Recently, the **American Medicines Agency (FDA)** granted full authorization to the **COVVI-19** vaccine developed by Novavax. This approval, however, came after a significant delay and has raised various concerns within the healthcare community.
**Novavax** initially sought the FDA’s approval for its vaccine, known as **Nuvaxovid**, after it had already received an emergency use authorization for individuals aged 12 and older. Alarmingly, the FDA had committed to making a decision before April 1, 2025, but ultimately failed to meet this timeline.
The delay sparked worries in the medical and pharmaceutical sectors, especially considering the **drastic overhaul** of health policies under the Trump administration. Prominent figures, such as **Robert Kennedy Jr.**, known for his **vaccine skepticism**, have been central to this reform.
Targeted Population: A Narrow Focus
While the FDA has now approved the **Nuvaxovid** vaccine, it has done so with restrictions, limiting its use to two specific population groups. As stated by **John Jacobs**, the president of Novavax, “Today’s approval consolidates the access of Americans aged 65 and over, and those aged 12 to 64 with comorbidities that expose them to a high risk of serious forms of COVVI-19 to a vaccine.”
“Nonetheless, the approval is seen as a step forward for public health,” Jacobs commented, though many experts are questioning the ramifications of such limited eligibility.
Article reserved for our subscribers
The “stars” of the pharmaceutical industry during the crisis due to COVVI-19 are seeking new opportunities.
Unlike the **mRNA vaccines** from **Pfizer-BioNTech** and **Moderna**, Novavax employs a more traditional vaccine technology approach, similar to that used in the **Janssen** vaccine. This difference highlights a significant diversity in vaccine development strategies amid the ongoing pandemic.
Concerns regarding the new restrictions on the Nuvaxovid vaccine raise questions about the vaccination strategies proposed by the newly appointed Health Minister, Robert Kennedy Jr. His history of spreading false information about vaccines—including misinformation during the measles epidemic—raises red flags, particularly with respect to public health policies in the United States.